SD Biotechnologies에스디생명공학

SD Biotechnologies remains loss-making, with a sharp fall in revenue since 2021 and a stock that has not moved in the data provided.

The Seoul-listed cosmetics and food company, which sells the SNP skincare brand and the Osam Sikta broth products, reported a trailing twelve-month revenue of about ₩25.6B and an operating loss of about ₩5.7B as of H1 2026. Its shares closed at ₩499 on 29 October 2026, with a market value of about ₩54.8B, and its recent filings are dominated by a share consolidation matter and a shareholders' meeting process. The data does not include any news coverage.

What stands out

• Revenue has fallen every year from about ₩124.7B in 2021 to ₩30.1B in 2025, and trailing revenue to H1 2026 is about ₩25.6B.
• Operating margin was -22.5% on a trailing basis and net margin was -26.9%, so losses remain deep relative to sales.
• Cash of about ₩6.0B against borrowings of about ₩2.3B, but trailing free cash flow was about -₩5.1B, which points to continued cash burn.
• The share price was flat at ₩499 across the 1-month, 3-month and 1-year periods, with the 52-week high and low both at ₩499.
• Recent filings include a trading halt, a delisting entry, a withdrawn share consolidation decision and an amended shareholders' meeting notice, all dated October 2026 or late September 2026.
• Price-to-book is about 2.0 and there is no price-to-earnings ratio because earnings are negative; no analyst ratings or price targets are included in the data.

What to watch

• The outcome of the shareholders' meeting and the status of the share consolidation, since the filing that proposed it was withdrawn in October 2026.
• Any further filings on the trading halt, the delisting entries and the postponed clearance sale, which the data does not explain in detail.
• Whether revenue and losses improve in upcoming half-year or annual results, given the continued operating losses and negative free cash flow.